Loading... Please wait...

Our Newsletter


AqueaTether™ (AqT™) Technologies

AqT™ Reagents and Kits

CellMosaic is developing next-generation conjugation kits and products based on our proprietary super-hydrophilic and high-loading AqueaTether™ (AqT™) linkers. AqT™ linkers are novel proprietary biomaterials with innovative chemical architectures invented at CellMosaic based on a class of natural and edible sugar alcohol compounds. AqT™ molecules are designed for labeling and conjugating biomolecules with very hydrophobic small molecules, such as fluorescent compounds, biotin, and small molecule drugs. Branched AqT™ crosslinking reagents can also be designed to allow high amounts of detecting molecules to be loaded onto a biomolecule for detection purposes. For AqT™ technologies in the application of drug development, please visit our website at www.aqttherapeutics.com

aqt-linker-technology-figure-1.png

Structure of AqT™ crosslinker

Sugar molecules are probably the most hydrophilic natural compounds to date due to their hydrogen bonding capability (donor and acceptor). Sugar alcohol, also known as polyol, is a hydrogenated form of carbohydrate in which the carbonyl group (aldehyde or ketone) has been reduced to a primary or secondary OH group. Sugar alcohols occur naturally in foods and come from plant products, such as fruits and berries. Sugar alcohols are often used as ingredients in sweeteners and for making polymers such as hydrogel. Table 1 list some popular sugar alcohols that can be used for making AqT™ crosslinkers.

3- Carbon 4- Carbon 5-Carbon 6-Carbon
Glycerol Erythritol Arabitol Mannitol
3-carbon-sugar-alcohol.png  Threitol Xylitol Sorbitol
 4-carbon-sugar-alcohol.png Ribitol Galactitol
5-carbon-sugar-alcohol.png  Fucitol
Iditol
6-carbon-sugar-alcohol.png 

 

 

 

 

 

 

 

 

 

 

Table 1: Sugar alcohols that can be used for making AqT™ crosslinkers.

 

Tunable Hydrophilicities of AqT™ linkers

1) AqT™ linkers are by far the most hydrophilic molecules in development

 aqt-technology-page-figure1.png

Figure 1. C18 HPLC analysis of AqT™ linker and other commercial linkers.

2) AqT™ linkers are by far the most versatile and tunable molecules in development. 

 properties2.jpg 

Figure 2. C18 column HPLC analysis of mono-dispersed AqT™ molecules of various SA units.

3) AqT™ crosslinker can be used to increase the water solubility of any hydrophobic compounds so that the conjugation can be done in aqueous buffer

 solubilities.jpg

Figure 3. C18 HPLC analysis of a hydrophobic drug before and after di-SA unit AqT™-linker labeling

 

Biopolymer Properties Unchanged after AqT™ Mediated Labeling and Conjugation with Small Molecules

aqt-biopolymer-h-bond-network.png

Biopolymer such as antibody, protein/peptide labeled with hydrophobic small molecules tend to aggregate and precipitate out from solution over time. AqT™ linker is used to modify these small molecules to increase its hydrophilicity and water solubility. The hydroxy (-OH) groups of AqT™ form a network of hydrogen bonds (H-bond) with neighboring water and create a microenvironment that shields neighboring small molecules or crosslinking moieties from stacking or interacting with one another. A biopolymer can be labeled with a high amount of AqT™-small molecule with no change to its properties. This AqT™ enhanced H-bond network also protects the polymers from enzymatic degradation and retains its activities.

  • AqT™ linker retains the properties of biopolymer
  • AqT™ technologies are true biocompatible for any biopolymer 

Examples: Antibody biotinylation using AqT™ T2A15 linker (see HPLC data in Figure 4, 5, and 6)

AqT™ T2A15 linker is composed of two threitols and 15 atom lengths. This atom length is equivalent to four polyethylene glycol modified biotin (PEG4) (16 atom lengths) except PEG4 does not increases any hydrophilicity of the biotin. 

aqt-technology-page-figure4.png

 

Figure 4. C18 HPLC analysis of biotin, AqT™ biotin, and biotin-PEG4.

AqT™ Biotin: less hydrophobic

    • Water soluble.
    • 100% aqueous solution for biotinylation

Biotin and PEGylated biotin: very hydrophobic

    • Sparsely water soluble.
    • Require some percentage of organic solvent for biotinylation. 

aqt-technology-page-figure5.png

 

 

Figure 5. Hydrophobic interaction chromatographic (HIC) analysis of antibody, biotin-antibody (DOL: 6.9), and AqT™ biotinylated antibodies with various loading.

AqT™ Biotin: Retain antibody properties

    • No changes in hydrophobicity
    • Minimal heterogeneity after labeling

Biotin: Change antibody properties

    • Increased hydrophobicity (non-specific interaction)
    • Highly heterogeneous product
aqt-technology-page-figure6.png

Figure 6. Size exclusion chromatographic (SEC) analysis of antibody, biotin-antibody (DOL: 6.9), and AqT™ biotinylated antibodies with various loading. 

AqT™ Biotin: Retain antibody properties

    • No increase of apparent MW (hydrodynamic volume)
    • No increase in aggregation

Biotin: Change antibody properties

    • Increased apparent MW (hydrodynamic volume)
    • May increase aggregation

 

 

Patent and license restrictions 

AqT™ molecules are covered under WO2013/012961A2, US patent number 8907079B2, 9511150B2, US15/281,023, Chinese 201280034231.3, Australian 2012284055, Japan 2014-521744, and equivalent patents and patent applications in other countries in the name of CellMosaic, Inc. We are currently marketing limited AqT™ products for internal research and development. 

The purchase of AqT™ products includes a limited license to use the AqT™ products for internal research and development but not for any commercial purposes. Commercial use shall include:

1. Sale, lease, license or other transfer of the material or any material derived or produced from it.

2. Sale, lease, license or other grant of rights to use this material or any material derived or produced from it.

3. Use of this material to perform services for a fee for third parties, including contract research and drug screening.

If you are interested in using AqT™ for commericial usage, please contact us for more information. For partnering and collaboration in the development of AqT™ therapeutics, please check our website at www.aqttherapeutics.com for more information.